Growth Metrics

Novavax (NVAX) Assets Average (2016 - 2025)

Historic Assets Average for Novavax (NVAX) over the last 17 years, with Q3 2025 value amounting to $1.3 billion.

  • Novavax's Assets Average fell 2873.56% to $1.3 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 billion, marking a year-over-year decrease of 2873.56%. This contributed to the annual value of $1.7 billion for FY2024, which is 1721.48% down from last year.
  • According to the latest figures from Q3 2025, Novavax's Assets Average is $1.3 billion, which was down 2873.56% from $1.3 billion recorded in Q2 2025.
  • In the past 5 years, Novavax's Assets Average ranged from a high of $2.7 billion in Q2 2022 and a low of $1.3 billion during Q3 2025
  • In the last 5 years, Novavax's Assets Average had a median value of $1.8 billion in 2024 and averaged $2.0 billion.
  • As far as peak fluctuations go, Novavax's Assets Average surged by 73645.43% in 2021, and later tumbled by 4086.07% in 2023.
  • Over the past 5 years, Novavax's Assets Average (Quarter) stood at $2.6 billion in 2021, then fell by 11.99% to $2.3 billion in 2022, then fell by 23.67% to $1.7 billion in 2023, then fell by 5.26% to $1.6 billion in 2024, then fell by 23.11% to $1.3 billion in 2025.
  • Its Assets Average stands at $1.3 billion for Q3 2025, versus $1.3 billion for Q2 2025 and $1.4 billion for Q1 2025.